Vital Therapies Inc Stock Nasdaq
Stocks
US92847R1041
Biotechnology & Medical Research
| Market Cap | 190M 165M 154M 141M 267M 18.17B 271M 1.81B 712M 9.04B 715M 699M 30.32B | P/E 2026 * |
-3.18x | P/E 2027 * | -3.84x |
|---|---|---|---|---|---|
| Enterprise Value | -111M -96.5M -89.82M -82.47M -156M -10.6B -158M -1.06B -416M -5.28B -417M -408M -17.69B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | -21.8x |
| Free-Float |
99.03% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -32.42% |
| Manager | Title | Age | Since |
|---|---|---|---|
Erik Lundgren
CEO | Chief Executive Officer | 48 | 01/06/2026 |
Glenn Whaley
DFI | Director of Finance/CFO | 58 | 17/04/2020 |
Jason Tardio
PSD | President | 49 | 12/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Vitt
BRD | Director/Board Member | 57 | 01/01/2019 |
Jörg Neermann
BRD | Director/Board Member | 59 | 01/04/2019 |
Duane Nash
CHM | Chairman | 55 | 01/01/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -32.42% | -43.31% | - | - | 190M | |
| +2.35% | +2.74% | +38.10% | +71.29% | 56.54B | |
| -0.21% | -7.38% | +27.52% | +61.15% | 53.6B | |
| -2.44% | +1.40% | -15.61% | -15.45% | 22.91B | |
| -2.85% | -7.78% | -9.28% | +345.55% | 21.37B | |
| +2.49% | -0.92% | +23.57% | -13.14% | 20.27B | |
| +0.79% | -1.06% | +33.99% | -31.95% | 17.56B | |
| +0.58% | -5.88% | +19.40% | +527.50% | 14.75B | |
| +3.41% | -6.61% | +162.81% | +278.22% | 13.53B | |
| -5.25% | -4.23% | +42.32% | +170.15% | 13.33B | |
| Average | -3.35% | -3.79% | +35.87% | +154.81% | 25.98B | |
| Weighted average by Cap. | +0.20% | -2.96% | +30.79% | +116.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 10M 8.69M 8.09M 7.43M 14.03M 955M 14.25M 95.38M 37.43M 475M 37.56M 36.73M 1.59B |
| Net income | -131M -114M -106M -97.43M -184M -12.52B -187M -1.25B -491M -6.23B -493M -482M -20.9B | -137M -119M -111M -102M -192M -13.05B -195M -1.3B -512M -6.5B -513M -502M -21.78B |
| Net Debt | -301M -262M -244M -224M -423M -28.76B -429M -2.87B -1.13B -14.32B -1.13B -1.11B -48.01B | -408M -355M -330M -303M -573M -38.98B -582M -3.89B -1.53B -19.4B -1.53B -1.5B -65.07B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
